Cubist Systematic Strategies LLC Acquires Shares of 77,750 ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Cubist Systematic Strategies LLC purchased a new position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 77,750 shares of the company's stock, valued at approximately $419,000. Cubist Systematic Strategies LLC owned approximately 0.28% of ClearPoint Neuro at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in CLPT. Point72 DIFC Ltd acquired a new stake in ClearPoint Neuro in the second quarter valued at approximately $32,000. XTX Topco Ltd lifted its holdings in shares of ClearPoint Neuro by 11.6% during the 2nd quarter. XTX Topco Ltd now owns 13,010 shares of the company's stock valued at $70,000 after purchasing an additional 1,353 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of ClearPoint Neuro by 7.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 24,867 shares of the company's stock worth $170,000 after purchasing an additional 1,813 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in ClearPoint Neuro during the 2nd quarter worth $175,000. Finally, Russell Investments Group Ltd. increased its position in ClearPoint Neuro by 23,048.0% during the 1st quarter. Russell Investments Group Ltd. now owns 46,296 shares of the company's stock valued at $315,000 after buying an additional 46,096 shares in the last quarter. 30.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CLPT shares. Lake Street Capital raised their price target on ClearPoint Neuro from $11.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, August 27th. B. Riley assumed coverage on shares of ClearPoint Neuro in a research note on Thursday, July 25th. They issued a "buy" rating and a $10.00 target price for the company.

ClearPoint Neuro Price Performance

CLPT traded up $0.80 on Monday, reaching $12.41. 493,937 shares of the stock were exchanged, compared to its average volume of 179,040. The company's 50-day moving average price is $11.25 and its 200 day moving average price is $7.90. The firm has a market capitalization of $340.28 million, a PE ratio of -14.77 and a beta of 1.10. ClearPoint Neuro, Inc. has a fifty-two week low of $4.05 and a fifty-two week high of $13.47.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.03. ClearPoint Neuro had a negative return on equity of 64.23% and a negative net margin of 64.06%. The firm had revenue of $7.86 million during the quarter, compared to the consensus estimate of $7.50 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. As a group, equities analysts forecast that ClearPoint Neuro, Inc. will post -0.65 earnings per share for the current fiscal year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.